Research map: SDHB and CDK1 protein expression in metastatic pheochromocytoma and paraganglioma

Back to the article

Papers in this map

  1. Germ-Line Mutations in Nonsyndromic Pheochromocytoma · Hartmut P.H. Neumann · 2002 · 1374 citations · Cited by this paper
  2. HbA1c screening in patients with early breast cancer receiving endocrine therapy · 2025 · Related
  3. Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma · Dewi Astuti · 2001 · 1100 citations · Cited by this paper
  4. Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas · 2025 · Related
  5. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms · Lester D.�R. Thompson · 2002 · 718 citations · Cited by this paper
  6. Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE · 2025 · Related
  7. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity · Patricia L. M. Dahia · 2014 · 551 citations · Cited by this paper
  8. 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence · 2025 · Related
  9. Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas · Laurence C. Amar · 2007 · 452 citations · Cited by this paper
  10. Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes · 2025 · Related
  11. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators · Montserrat Ayala‐Ramirez · 2010 · 432 citations · Cited by this paper
  12. To screen or not to screen: complexity of SDHA mutation management · 2026 · Related
  13. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension · Jacques W.M. Lenders · 2020 · 414 citations · Cited by this paper
  14. Adrenal crisis due to pembrolizumab-induced hypophysitis in a patient with triple-negative breast cancer · 2025 · Related
  15. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma · Noriko Kimura · 2014 · 394 citations · Cited by this paper
  16. Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer · 2025 · Related
  17. Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla · Alessandro Furlan · 2017 · 378 citations · Cited by this paper
  18. Patient-reported symptom and urgent healthcare use in neuroendocrine tumors · 2026 · Related
  19. High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing · Frederieke M. Brouwers · 2006 · 315 citations · Cited by this paper
  20. Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute · 2025 · Related
  21. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes · Anthony James Gill · 2010 · 277 citations · Cited by this paper
  22. Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score · David M. Wu · 2009 · 174 citations · Cited by this paper
  23. Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study · Hana Turková · 2015 · 139 citations · Cited by this paper
  24. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma · Jung‐Min Koh · 2017 · 115 citations · Cited by this paper
  25. Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma · Bruna Calsina · 2023 · 106 citations · Cited by this paper
  26. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems · Heather Wachtel · 2020 · 103 citations · Cited by this paper
  27. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas · Charlie Pierre · 2019 · 82 citations · Cited by this paper
  28. Pheochromocytomas and paragangliomas: assessment of malignant potential · Tim I.M. Korevaar · 2011 · 71 citations · Cited by this paper
  29. Usefulness of Negative and Weak–Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and Pheochromocytomas · Esmeralda Castelblanco · 2013 · 51 citations · Cited by this paper
  30. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma · Christina Pamporaki · 2022 · 46 citations · Cited by this paper
  31. Malignant pheochromocytomas/paragangliomas harbor mutations in transport and cell adhesion genes · Annica Wilzén · 2015 · 37 citations · Cited by this paper
  32. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis · Tingwei Su · 2023 · 22 citations · Cited by this paper
  33. Very late recurrence of an apparently benign pheochromocytoma · Elena Thai · 2015 · 14 citations · Cited by this paper
  34. Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma · Sinan Karakaya · 2023 · 7 citations · Cited by this paper
  35. Prediction model for pheochromocytoma/paraganglioma using nCounter assay · Young Lyun Oh · 2024 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)